The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a stabilizing medical technology sector, Medtronic has received a buy rating with a $92 price target based on conservative fiscal 2027 guidance. According to reports, the company delivered $36.4 billion in revenue for fiscal 2026, marking its strongest growth performance in a decade. This momentum is largely driven by robust performance in cardiovascular solutions, suggesting that the company's cautious outlook for the coming year leaves significant room for upside surprises.
Compared to industry peers, Medtronic’s trajectory remains competitive; for instance, Abbott Laboratories reported an 8.2% organic sales growth in its latest quarter per earnings data, while MDT trades at a compelling valuation relative to historical averages. Market experts suggest that current analyst models may not yet fully price in catalysts such as the potential MiniMed separation or relief from Blackstone payment obligations, which could serve as medium-term tailwinds.
Sign in to access this content
Sign InMedtronic (MDT) shares closed at $82.01 (close July 8, 2026), indicating a potential upside of approximately 12% to reach the analyst target. Traders are currently monitoring support levels near the July 8 low of $81.87. Looking ahead, market participants will be watching the upcoming ISM Services PMI data in the US for broader insights into service-sector costs and domestic demand dynamics that could impact healthcare providers.